SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 5,000 Shares of Company Stock

Key Points

• Insider sale: Philippe Menu sold 5,000 SOPHiA GENETICS shares at an average price of $7.26, reducing his position by 2.49% to 195,993 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Stock and financial performance: SOPH recently traded around $7.06, with a 12-month range of $3.75 to $8.98. Its latest quarter missed earnings expectations, reporting a $0.26 loss per share despite revenue exceeding estimates.
• Analyst outlook is mixed: The stock has an average “Hold” rating and a consensus price target of $10.00, with ratings ranging from Buy to Sell. Institutional investors own approximately 31.59% of the company.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of the business's stock in a transaction on Monday, October 12th. The stock was sold at an average price of $7.26, for a total transaction of $36,300.00. Following the completion of the sale, the insider owned 195,993 shares in the company, valued at approximately $1,422,909.18. The trade was a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, October 5th, Philippe Menu sold 7,394 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total transaction of $60,113.22.
• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.68, for a total value of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock traded down $0.03 during midday trading on Wednesday, reaching $7.06. 376,763 shares of the stock traded hands, compared to its average volume of 310,258. The stock's fifty day moving average is $7.95 and its 200-day moving average is $6.20. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98. The stock has a market cap of $592.26 million, a P/E ratio of -6.14 and a beta of 0.95. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SOPH. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of SOPHiA GENETICS in a report on Monday. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research upped their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and an average price target of $10.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS during the first quarter worth approximately $50,000. Royal Bank of Canada raised its position in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock valued at $96,000 after purchasing an additional 18,781 shares during the period. AXQ Capital LP bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $119,000. Silverberg Bernstein Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock valued at $257,000 after purchasing an additional 4,155 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $567,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.